# Low Grade Lymphoma

> **NCT01698866** · PHASE4 · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 40 (estimated)

## Conditions studied

- Indolent Lymphoproliferative Disorders

## Interventions

- **BIOLOGICAL:** Vaccin GenHevac B Pasteur

## Key facts

- **NCT ID:** NCT01698866
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2017-07
- **Final completion:** 2018-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01698866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01698866, "Low Grade Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01698866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*